After the FDA posted briefing documents ahead of an Advisory Committee meeting to be held on March 22, BofA said the firm’s review of the document suggests that the FDA is "likely in favor" of tofersen approval for SOD1-ALS given the significant unmet need. In addition, the firm’s key opinion leader contact believes tofersen will be approved given his own and his colleagues’ clinical experience, where some patients got better overtime, notes BofA. The firm has a Neutral rating and $295 price target on Biogen shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- FDA posts briefing document for advisors’ review of Biogen’s ALS drug
- Stifel trims Biogen target, but has more confidence lecanemab ‘best-in-class’
- Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
- Biogen receives favorable court ruling on TECFIDERA
- Needham healthcare analyst to hold an analyst/industry conference call